Torisel and Epistaxis - a phase IV clinical study of FDA data

Summary:

Epistaxis is reported as a side effect among people who take Torisel (temsirolimus), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Sunitinib Malate, and have Renal cell carcinoma.

The phase IV clinical study analyzes which people have Epistaxis when taking Torisel. It is created by eHealthMe based on reports of 3,194 people who have side effects when taking Torisel from the FDA, and is updated regularly.

What is Torisel?

Torisel has active ingredients of temsirolimus. eHealthMe is studying from 3,205 Torisel users. Check the latest studies of Torisel.

What is Epistaxis?

Epistaxis (bleed from the nose) is found to be associated with 3,181 drugs and 3,092 conditions by eHealthMe. Check the latest studies of Epistaxis.

On Apr, 13, 2026

3,194 people reported to have side effects when taking Torisel.
Among them, 36 people (1.13%) have Epistaxis.

Among these 36 people:

How long have people been on Torisel when they have Epistaxis? *

What is the gender of people who have Epistaxis when taking Torisel? *

female: 3.12 %
male: 96.88 %

What is the age of people who have Epistaxis when taking Torisel? *

What are other drugs people take besides Torisel? *

What are other side effects people have besides Epistaxis? *

Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 18 people, 50.00%
Weakness: 15 people, 41.67%
Fatigue (feeling of tiredness): 15 people, 41.67%
Nausea (feeling of having an urge to vomit): 15 people, 41.67%
Drowsiness: 13 people, 36.11%
Conjunctivitis (pink eye): 13 people, 36.11%
Nasal Discomfort: 13 people, 36.11%
Disease Progression: 11 people, 30.56%
Thrombocytopenia (decrease of platelets in blood): 10 people, 27.78%
Renal Cell Carcinoma (a kidney cancer): 9 people, 25.00%

What are the existing conditions these people have? *

Renal Cell Carcinoma (a kidney cancer): 20 people, 55.56%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 7 people, 19.44%
Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 3 people, 8.33%
Pain: 2 people, 5.56%
Neoplasm Malignant (cancer tumour): 2 people, 5.56%
Colon Cancer: 2 people, 5.56%
Renal Cell Carcinoma Stage Unspecified (kidney cancer in unknown stage): 1 person, 2.78%
Renal Cancer Metastatic (cancer of kidney spreads to other part): 1 person, 2.78%
Paroxysmal Nocturnal Haemoglobinuria (haemoglobin in the urine): 1 person, 2.78%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Torisel and have Epistaxis?

- Check whether Epistaxis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Torisel:

Torisel (3,205 reports)

Epistaxis treatments and more:

Epistaxis (92,075 reports)

Browse all side effects of Torisel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Epistaxis:

Epistaxis (3,181 drugs)

Browse all the conditions that are associated with Epistaxis:

Epistaxis (3,092 conditions)

Related publications that referenced our studies

Herrin MA, Rubinstein JC, Christison-Lagay ER, "Temsirolimus therapy and small bowel perforation in a pediatric patient with Clostridium septicum bacteremia", Journal of Pediatric Surgery Case Reports, 2015 Aug .
Herrin MA, Rubinstein JC, Christison-Lagay ER, "Temsirolimus therapy and small bowel perforation in a pediatric patient with Clostridium septicum bacteremia", Journal of Pediatric Surgery Case Reports, 2015 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on temsirolimus (the active ingredients of Torisel) and Torisel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.